Literature DB >> 22331597

Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference.

Jie Chen1, Xiaoyan Liu, Jie Zhang, Yueran Zhao.   

Abstract

High-mobility group box 1 (HMGB1), a nuclear and extracellular protein, is implicated in the development and progression of some types of cancers. However, no information is available to date regarding the function of HMGB1 in ovarian cancer. In this study, we performed cDNA microarray analysis and identified HMGB1 as a gene dramatically elevated in the highly invasive subclone S1 compared with the low invasive subclone S21 derived from the same cell line SKOV3. Then lentivirus vector with HMGB1 shRNA was constructed and infected the highly invasive cell line S1, A1, and HO8910PM. Real-time RT-PCR, Western blot, and IHC results confirmed the down-regulation of HMGB1 expression by its shRNA was about 80-90% at both the mRNA and protein levels. Knockdown of HMGB1 significantly suppressed ovarian cancer cell proliferation and induced cell cycle arrest at the G1/G0 phase, which was accompanied by decreased expressions of cyclin D1 and PCNA. Furthermore, knockdown of HMGB1 induced ovarian cancer cell apoptosis, which was mediated by increased expression of Bax and decreased expression of Bcl-2. Finally, knockdown of HMGB1 significantly inhibited ovarian cancer cell invasion and metastasis, which was regulated by decreased expressions of MMP2 and MMP9. Serum HMGB1 levels in patients with epithelial ovarian cancer were significantly higher than that in patients with benign ovarian tumor and healthy controls. These results indicate that HMGB1 is a newly identified gene associated with ovarian cancer growth and metastasis. HMGB1 may serve as a new therapeutic target for the treatment of ovarian cancer in the future.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331597     DOI: 10.1002/jcp.24069

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.

Authors:  Wen Shu
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

Review 2.  HMGB1 in hormone-related cancer: a potential therapeutic target.

Authors:  Madhuwanti Srinivasan; Souresh Banerjee; Allison Palmer; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam
Journal:  Horm Cancer       Date:  2014-04-10       Impact factor: 3.869

3.  Ultraviolet light exposure stimulates HMGB1 release by keratinocytes.

Authors:  Kelly E Johnson; Brian C Wulff; Tatiana M Oberyszyn; Traci A Wilgus
Journal:  Arch Dermatol Res       Date:  2013-08-13       Impact factor: 3.017

4.  Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.

Authors:  H Yang; L Pellegrini; A Napolitano; C Giorgi; S Jube; A Preti; C J Jennings; F De Marchis; E G Flores; D Larson; I Pagano; M Tanji; A Powers; S Kanodia; G Gaudino; S Pastorino; H I Pass; P Pinton; M E Bianchi; M Carbone
Journal:  Cell Death Dis       Date:  2015-06-11       Impact factor: 8.469

5.  Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis.

Authors:  Haipeng Wang; Zengjun Li; Yanlai Sun; Zhongfa Xu; Jianjun Han; Bao Song; Wentao Song; Chen Qin; Lei Yin
Journal:  Onco Targets Ther       Date:  2015-11-27       Impact factor: 4.147

Review 6.  High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer.

Authors:  Aida Barreiro-Alonso; Mónica Lamas-Maceiras; Esther Rodríguez-Belmonte; Ángel Vizoso-Vázquez; María Quindós; M Esperanza Cerdán
Journal:  Oxid Med Cell Longev       Date:  2015-11-23       Impact factor: 6.543

7.  HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma.

Authors:  Qingbing Meng; Jie Zhao; Hongbing Liu; Guoyou Zhou; Wensheng Zhang; Xingli Xu; Minqian Zheng
Journal:  Tumour Biol       Date:  2014-08-29

8.  Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.

Authors:  Zhichao Huang; Zhaohui Zhong; Lei Zhang; Xinjun Wang; Ran Xu; Liang Zhu; Zijian Wang; Shanbiao Hu; Xiaokun Zhao
Journal:  Sci Rep       Date:  2015-08-04       Impact factor: 4.379

9.  Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.

Authors:  Jie Chen; Deying Wei; Yueran Zhao; Xiaoyan Liu; Jie Zhang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET.

Authors:  Xiu-Jie Sheng; Zhen Li; Man Sun; Zhi-Hui Wang; Dong-Mei Zhou; Jian-Qi Li; Qin Zhao; Xiao-Fang Sun; Qi-Cai Liu
Journal:  Oncol Lett       Date:  2014-05-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.